The purpose of this work was to investigate the efficacy and safety of sildenafil in combination with doxazosin for the treatment of non-organic erectile dysfunction in patients who did not respond to sildenafil. We enrolled 28 patients with non-organic erectile dysfunction, for whom 3 months of sildenafil monotherapy had failed. They were divided in two random and homogeneous groups: 14 were treated with doxazosin (4 mg daily) and sildenafil (100 mg 1 h before sexual intercourse); the other 14 patients received sildenafil and placebo. The results were assessed by means of the IIEF questionnaire before the beginning of the study, after 30 days of therapy and after 60 days. Of the 14 patients treated with doxazosin and sildenafil, 11 (78.6%) showed a statistically significant increase of IIEF; in the placebo group, only one patient (7.1%) recorded a significant IIEF increase. The differences observed in the two groups were statistically very significant (P ¼ 0.0016). Blood pressure did not show significant alterations. Side effects were minimal and even present during sildenafil monotherapy. The combination therapy with sildenafil and doxazosin resulted in the safe and effective treatment of men with non-organic erectile dysfunction for whom sildenafil alone had failed.
Introduction
The prevalence of erectile disorders in the world's male population has reached high values: according to recent epidemiological studies, more than 30 million men in the United States are affected by erectile dysfunction (ED) of varying severity. 1 Due to progressive prolongevity, it goes without saying that the impact of this problem will continue to grow.
The introduction of new oral drugs such as sildenafil has radically transformed the therapeutic approach of ED, reducing the use of other therapeutic options such as intracavernosal pharmacotherapy, intraurethral prostaglandin (MUSE), vacuum constrictor devices, vascular surgery and penile prostheses. It has generally been accepted that patients presenting with ED are treated with sildenafil regardless of etiology. 2 Even though the efficacy and tolerability of sildenafil are extremely high, failure rates of 30 -35% are however reported. 3, 4 The inhibitory action of the sympathetic nervous system and of the alpha-adrenergic mediators on erection have been exhaustively documented; 5 -7 good results for ED achieved with alpha-blockers have also been reported after intracavernosal injection as well as oral administration. 8 -12 Doxazosin is an alpha 1 -blocker commonly used in the oral therapy for hypertension and benign prostatic hyperplasia, and therefore considered worth trying.
The aim of our study was to investigate the efficacy and safety of combined sildenafil -doxazosin oral therapy for non-organic ED patients who did not respond to sildenafil monotherapy.
Materials and methods
During the last year, 28 patients with chronic ED who had failed at least 12 weeks of sildenafil (100 mg) therapy were enrolled in this prospective, randomized and placebo-controlled study. The age of patients varied between 36 and 62 y (average 51), while the ED had persisted from 8 months to 3 y. All patients were referred to our public andrological office; all were heterosexual, 21 (75%) were married and 7 (25%) had a stable partner. Exclusion criteria included patients with significant cardiovascular disease, unbalanced diabetes mellitus, neurological and psychiatric disorders, previous genitourinary surgery, or a history of intolerance to alpha-blockers. A normal blood testosterone, a normal nocturnal penile tumescence and rigidity (evaluated by NPTRRigiScan) and normal dynamic duplex ultrasound were adopted as inclusion criteria. During the dynamic tests, the intracavernosal injection of 10 mg of prostaglandin E 1 (PGE 1 ) produced an erection of sufficient stiffness and duration in all patients. On the basis of the outcomes of these diagnostic tests, we can define the ED as 'nonorganic' or 'without an identifiable organic aetiology'. We can not nevertheless label these patients as suffering from psychogenic ED, because no psychometric tests were performed; however none of the patients were afflicted with psychiatric disorders or were on psychotropic medications.
The patients where randomized in two homogenous groups: 14 of them received daily doxazosin titrated to 4 mg and 100 mg of sildenafil 1 h before sexual intercourse; the other 14 patients, apart from the 100 mg of sildenafil before intercourse, received a placebo instead of doxazosin.
The results were assessed by means of the erectile function domain of the IIEF 13 questionnaire before the beginning of the study (V0), after 30 days of therapy (V1) and after 60 days (V2). During treatment, all patients had at least two sexual encounters weekly. During each clinic visit blood pressure measurements were taken. The IIEF scores of the two groups were statistically compared with ANOVA; for each group the results during the various visits were also assessed using Friedman's non-parametric test and the corresponding internal changes. The comparison between the frequency of cases that responded positively in the two groups was carried out using Fischer's exact probability test.
Results
Of the 14 patients treated with doxazosin and sildenafil, 11 (78.6%) showed a statistically significant increase of IIEF, moving on average from 13.0 (V0) to 21.2 (V2). In the placebo group, only one patient (7.1%) recorded a significant IIEF increase from 12 (V0) to 22 (V2), while all the others experienced no changes in the IIEF score.
Result assessment of the two groups in terms of IIEF score highlighted a significant difference (P ¼ 0.0016) to the advantage of the group treated with sildenafil þ doxazosin compared with the one treated with sildenafil þ placebo. It should be noted that the positive progression of the IIEF score vis-à-vis the assessment phases (V0, V1 and V2) is highly significant (P < 0.0001) and that the response to the pharmacological association between sildenafil and doxazosin shows a significant score increases as early as the second visit (P ¼ 0.0023). Tables 1 and 2 show results in detail.
In two of the 11 patients who responded positively to the sildenafil -doxazosin association, it was possible to lower sildenafil dosage to 50 mg. In particular, eight of the 11 positive responders (72.2%) said that they achieved erection far more easily and without fatigue and of having managed to keep their penis constantly erect during the entire intercourse.
Blood pressure monitoring did not point out significant oscillations: 130 mm Hg AE 10=80 AE 5 at V0 and 120 mm Hg AE 10=75 AE 5 at V2. None of the patients mentioned lipothymic episodes. Two patients in the sildenafil -doxazosin group reported facial flushing and one a mild headache. One patient reported heartburn, which was treated with antacids. In the placebo group a patient reported mild headache. Of all the reported side effects, heartburn was the only addition to the sildenafil -doxazosin association: all the others were present before treatment.
Discussion
Today, sildenafil is the therapy of choice for patients presenting with ED regardless of etiology. 2 Recent 15 However, a reasonable share of sildenafil non-responders have a non-organic ED: Rosen recently reported that psychosexual therapy in combination with sildenafil is effective for patients who do not respond to sildenafil monotherapy. 16 In the light of our experience, most patients with non-organic ED refractory to sildenafil respond well to the sildenafil -doxazosin association. Therefore, we believe that these refractory patients, before starting more invasive second-line treatments, should undergo diagnostic evaluations in order to understand the etiology of their ED. In presence of non-organic ED patients, a combined treatment with sildenafil, doxazosin and=or psychosexual therapy should be used.
The rationale of combined therapy with respect to monotherapy, is that of increasing the efficacy and, at the same time, reducing the side effects of the treatment itself. If we look at intracavernosal pharmacotherapy, for example, it has been shown that the combination of phentolamine and prostaglandin E 1 (alprostadil) or of phentolamine and papaverine may achieve better results (in terms of efficacy and tolerability) than monotherapy. 8 Pathma-Nathan even recommended the use of triple therapy: phentolamine, alprostadil and papaverine. 17 In the last years, the treatment of ED was revolutionized by the introduction of new drugs that may be administered orally. Apart from sildenafil, apomorphine, 18,19 phentolamine, 9 -11 doxazosin, 12 yohimbine 20 and vardenafil 21 have recently been used. The efficacy of these drugs has not yet been determined in a final way and no comparative clinical trials versus sildenafil have been performed.
In the past, as far as we are aware of, no articles have been published on combined therapy that exclusively envisages oral drugs. In 1998, Kaplan 12 published a paper on combined therapy that included oral doxazosin and intracavernosal prostaglandin (alprostadil) in patients with ED in whom the mere intracavernosal pharmacotherapy proved to be ineffective. In these patients, the doxazosin association with a dosage of 4 mg allowed for a statistically significant improvement of the erectile deficit: in particular, patients reported quicker erections and a constant erection during the entire intercourse. Side effects did not increase and blood pressure showed no significant alterations. In 2000, Mydlo 22 reported that 60 of 65 patients (92%) with ED and minimal or no response to intracavernosal alprostadil or sildenafil monotherapy had satisfactory responses with combination therapy (sildenafil and alprostadil). In 2001, Nehra 23 used a combination of sildenafil (100 mg) and MUSE (500 mg) for refractory ED patients and reported a 100% success rate at 18-month follow-up.
The sympathetic nervous system, via release of noradrenaline and stimulation of alpha 1 adrenergic receptors, is considered to be the prime determinant of cavernosal smooth muscle contraction and detumescence. 6 The tonic activity of the sympathetic system keeps the penis in the flaccid state by means of the continuous stimulation of alpha adrenoceptors present in penile erectile tissue (helicine vessels and cavernosal trabecular smooth muscle) resulting in vasoconstriction. This explains the positive action of anti-adrenergic drugs on the penile erection disorders, whether these are administered at local intracavernosal level or at systemic level by means of oral administration. These drugs remove the inhibitory sympathetic tone and allow the cavernosal smooth muscle cells to relax, with consequent increase of blood flow inside the lacunar spaces. Phentolamine, a non-specific adrenergic inhibitor active on both alpha 1 and alpha 2 adrenoceptors, has been successfully employed in intracavernosal pharmacotheraphy. 8, 17 Some studies have pointed out its possible role even after oral or buccal administration. Zorgniotti reported a 42% rate of full spontaneous erections after buccal administration of 50 mg of phentolamine. 9 Becker has carried out a double-blind placebo-controlled study in 40 men with ED treated with varying doses of phentolamine: full erections were achieved by 20% of the placebo group, 30% in the group treated with 20 mg and 50% in the group with 50 mg. 10 Recently, Goldstein has reported the results of large multicenter, placebo-controlled pivotal phase III clinical trials: the mean change in the erectile function was significantly higher following use of phentolamine (40 mg or 80 mg) compared to placebo and there were no severe adverse events. 11 Doxazosin is an alpha 1 selective anti-adrenergic drug; there are few studies on its oral use for ED therapy. Apart from Kaplan's above-mentioned paper, 12 we can report Grimm et al's recent experience on the study of long-term effects of five antihypertension drugs on sexual dysfunction: after 2 y of therapy, the lower incidence of ED (2.8%) was found in the subgroups of patients treated with doxazosin (compared to 5% in the group of patients who received a placebo). 24 Doxazosin's action on penile alpha 1 -adrenergic receptors was shown with experiments in primates, where intracavernosal injection with doxazosin enabled full erections. 12 Combined oral therapy of non-organic ED AF De Rose et al
The contractile cavernosal tissue is regulated by two systems: on the one hand the sympathetic nervous system mediated by noradrenaline with an inhibitory action on erection (ie vasoconstriction), and on the other hand the non-adrenergic system with stimulating action (ie vasodilation). The relaxation of the smooth muscle cells present in the intracavernosal vascular structures induced by the non-adrenergic systems has, as the ultimate mediator, nitric oxide. Sildenafil's action, by inhibiting 5-phosphodiesterase, favors the release of this powerful vasodilator. This explains the rationale of sildenafil -doxazosin combined therapy: doxazosin's anti-adrenergic action reduces the inhibitory tone of the sympathetic system hence favoring sildenafil's stimulation of the non-adrenergic system with a vasodilating action. This is the only way to possibly explain the faster erections and the more constant rigidity reported by most of our patients who positively responded to the sildenafil and doxazosin association.
Since the efficacy and tolerability of sildenafil are well known, combined therapy with doxazosin must not be administered as the first option for patients with ED, but should only be used in patients with non-organic ED who do not respond to monotherapy.
Conclusions
The results of our study highlight the synergistic role of sildenafil and doxazosin in the oral therapy of non-organic ED. The use of an anti-adrenergic drug reduces penile vasoconstrictive sympathetic tone enhancing the vasoactive effects of sildenafil. The sildenafil -doxazosin association showed neither an increase in side effects nor significant blood pressure alterations.
